Adaptation of the WOMAC for Use in a Patient Preference Study

[1]  C. Poulos,et al.  MSR17 Logical Soundness in a Discrete Choice Experiment Study of Benefit Risk Preferences , 2022, Value in Health.

[2]  A. Bate,et al.  Systematic Review of Studies Using Conjoint Analysis Techniques to Investigate Patients’ Preferences Regarding Osteoarthritis Treatment , 2021, Patient preference and adherence.

[3]  M. Kloppenburg,et al.  Emerging pharmaceutical therapies for osteoarthritis , 2020, Nature Reviews Rheumatology.

[4]  C. Cooper,et al.  A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCEO working group. , 2020, Seminars in arthritis and rheumatism.

[5]  S. Grässel,et al.  Recent advances in the treatment of osteoarthritis , 2020, F1000Research.

[6]  A. Guermazi,et al.  Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period , 2020, Annals of the Rheumatic Diseases.

[7]  H. Benz,et al.  Integrating the Voice of the Patient Into the Medical Device Regulatory Process Using Patient Preference Information. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  I. Huys,et al.  Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. , 2019, Drug discovery today.

[9]  A. Holtorf,et al.  Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs , 2019, Front. Med..

[10]  R. Fitzpatrick,et al.  Duration of Treatment Effect Should Be Considered in the Design and Interpretation of Clinical Trials: Results of a Discrete Choice Experiment , 2019, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  Alan R. Ellis,et al.  Discrete Choice Experiments in Health Economics: Past, Present and Future , 2018, PharmacoEconomics (Auckland).

[12]  R. Fitzpatrick,et al.  Problems persist in reporting of methods and results for the WOMAC measure in hip and knee osteoarthritis trials , 2018, Quality of Life Research.

[13]  D. Felson,et al.  Responsiveness of Single versus Composite Measures of Pain in Knee Osteoarthritis , 2018, The Journal of Rheumatology.

[14]  D. Gregori,et al.  Evaluating therapeutic effect on WOMAC subscales in osteoarthritis RCTs: When model choice matters , 2018, Journal of evaluation in clinical practice.

[15]  C. Kwoh,et al.  Epidemiology of osteoarthritis: literature update , 2017, Current opinion in rheumatology.

[16]  J. Sim,et al.  Generating Individual Patient Preferences for the Treatment of Osteoarthritis Using Adaptive Choice-Based Conjoint (ACBC) Analysis , 2017, Rheumatology and Therapy.

[17]  Anindita Saha,et al.  A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  Elena Losina,et al.  Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity , 2016, Arthritis care & research.

[19]  P. Smith,et al.  Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis , 2016 .

[20]  A. Carr,et al.  Osteoarthritis , 2015, The Lancet.

[21]  M. Fransen,et al.  Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS) , 2013, BMC Musculoskeletal Disorders.

[22]  S. Sen,et al.  A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. , 2013, Osteoarthritis and cartilage.

[23]  N. Woolacott,et al.  The use and reporting of WOMAC in the assessment of the benefit of physical therapies for the pain of osteoarthritis of the knee: findings from a systematic review of clinical trials. , 2012, Rheumatology.

[24]  Andrew Lloyd,et al.  Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  J. Farrar,et al.  Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database. , 2011, Osteoarthritis and cartilage.

[26]  A. Leclerc,et al.  Impact of osteoarthritis: results of a nationwide survey of 10,000 patients consulting for OA. , 2005, Joint, bone, spine : revue du rhumatisme.

[27]  J. Concato,et al.  Treatment options in knee osteoarthritis: the patient's perspective. , 2004, Archives of internal medicine.

[28]  J. Concato,et al.  Informed choice and the widespread use of antiinflammatory drugs. , 2004, Arthritis and rheumatism.

[29]  M. Buxton,et al.  Patients' preferences for characteristics associated with treatments for osteoarthritis. , 2003, Rheumatology.

[30]  A. Davis,et al.  The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. , 2001, Arthritis and rheumatism.

[31]  C. Goldsmith,et al.  Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. , 1988, The Journal of rheumatology.

[32]  L. Engebretsen,et al.  Clinical Outcomes of Knee Osteoarthritis Treated With an Autologous Protein Solution Injection: A 1-Year Pilot Double-Blinded Randomized Controlled Trial , 2018, American Journal of Sports Medicine.

[33]  Telba Irony,et al.  Incorporating patient-preference evidence into regulatory decision making , 2014, Surgical Endoscopy.

[34]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  Mickael Bech,et al.  Designing a stated choice experiment: The value of a qualitative process , 2012 .